Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 237

Results For "Science"

2393 News Found

Aceto acquires specialty exipients company A&C
News | April 16, 2021

Aceto acquires specialty exipients company A&C

Acquisition of A&C expands Aceto’s Western manufacturing footprint


Merck publishes sustainability report for 2020
News | April 13, 2021

Merck publishes sustainability report for 2020

The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.


Aurore to merge with Solara in an all-stock transaction
News | April 10, 2021

Aurore to merge with Solara in an all-stock transaction

The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions


Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b in treating COVID-19
News | April 05, 2021

Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b in treating COVID-19

PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents


COVID-19 drug Remdesivir now priced at Rs. 899
News | March 25, 2021

COVID-19 drug Remdesivir now priced at Rs. 899

Zydus has made its brand of Remdesivir, Remdac more affordable at Rs. 899 for a 100 mg lyophilized injection.


Merck accelerates expansion plans for single-use products critical to manufacturing vaccines
News | March 18, 2021

Merck accelerates expansion plans for single-use products critical to manufacturing vaccines

The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.


Merck brings new renewable energy to the grid through VPPA with Enel Green Power
News | March 18, 2021

Merck brings new renewable energy to the grid through VPPA with Enel Green Power

Has signed a 12-year, off-site, virtual power purchase agreement (VPPA) with Enel Green Power


Govt. receives 215 applications for the 36 products under PLI scheme
News | March 13, 2021

Govt. receives 215 applications for the 36 products under PLI scheme

174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.


UPM Biomedicals and CELLINK collaborates for 3D bioprinting developments
News | March 11, 2021

UPM Biomedicals and CELLINK collaborates for 3D bioprinting developments

The collaboration of two strong partners, CELLINK and UPM, builds confidence in making these treatments into an industrial and clinical standard, applied in a wider setting instead of remaining only within few hospitals.